ArticleJournal of conservative dentistry and endodontics2026
Interappointment pain reduction with three intracanal medicaments: A randomized clinical trial.
Article in Journal of conservative dentistry and endodontics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aim: The aim of this study was to evaluate and compare the efficacy of calcium hydroxide, modified triple antibiotic paste (mTAP), and ferumoxytol as intracanal medicaments in reducing interappointment pain during endodontic treatment. Subjects and Methods: A randomized Statistical Analysis: Data were conducted using one-way analysis of variance, followed by Tukey's Results: All three medicaments reduced interappointment pain but with varying degrees of effectiveness. Ferumoxytol demonstrated the most consistent reduction in pain scores, followed by mTAP, while calcium hydroxide showed comparatively higher residual pain levels. Statistical analysis revealed significant differences among the groups ( Conclusions: Ferumoxytol emerges as a promising intracanal medicament with targeted biofilm disruption and reduced drawbacks compared to conventional agents. Its clinical potential in minimizing interappointment pain highlights its relevance as an alternative to calcium hydroxide and mTAP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.